Safety Issues Clinical Trial
Official title:
A Single Center, Pilot Study to Evaluate the Feasibility of the Percutaneous Ultrasound Jejunostomy (PUJ)
Verified date | October 2023 |
Source | CoapTech |
Contact | Clinical Trials |
Phone | 443 574 6934 |
regulatory[@]coaptech.com | |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to evaluate the feasibility and performance of the Percutaneous Ultrasound Jejunostomy (PUJ) procedure that utilizes a novel device (PUMA-J System) in conjunction with widely available ultrasound technology and endoscopic guidance. The procedure will be performed in up to 10 eligible subjects. Patients will be followed for 2 days following performance of PUJ to assess for potential complications.
Status | Not yet recruiting |
Enrollment | 10 |
Est. completion date | July 1, 2025 |
Est. primary completion date | June 1, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 22 Years and older |
Eligibility | Inclusion Criteria: - Informed consent must be obtained before any study-specific assessment is performed - Male or female > 21 years of age - Estimated tract length (skin to anterior abdominal wall) <= 4.5cm on prior imaging - Indication for percutaneous jejunostomy tube placement determined to be present by the primary clinical care team (examples below): - High aspiration risk - Malnourished- chronically ill and/or neurologically impaired requiring jejunal feeding for >30 Days. - Neoplasia (stomach and esophagus) - Gastric and duodenal obstruction - Gastrointestinal dysmotility (gastroparesis) - Altered anatomy (gastric-esophageal surgeries) - Other indication deemed to be appropriate by the study team - Patient determined to be an appropriate candidate for percutaneous jejunostomy by the study team - Women of childbearing potential must have negative serum or urine pregnancy test during the current hospitalization Exclusion Criteria: - Temperature = 38 C - Systolic BP < 90 or > 180 mmHg - Heart Rate < 50 or > 120 - Presence of a contraindication to being in proximity to a magnet (e.g. pacemaker) - History of prior major abdominal surgery - Patients with HgB < 7g/dL, or fluid resuscitated within 48hrs prior, or history of life-threatening gastrointestinal bleeding within 1 month - Pregnant or nursing (lactating) women - Involvement in other investigational trials within 30 days prior to screening - Absolute contraindications: - Sepsis - Severe ascites - Peritonitis - Coagulopathy (international normalized ratio (INR) greater than 1.5 or a platelet count of less than 50,000/uL) - Abdominal wall infection at the site of planned tube insertion - Interposed organs as determined by imaging - Abnormal upper gastrointestinal anatomy (e.g., partial or Total gastrectomy, Esophageal strictures) - Inflammatory, or infiltrative diseases of the small bowel and/or anterior abdominal wall. - Other standard general contraindications to endoscopy - Pacemakers or other electronically active implantable devices - Small bowel fistula - Any other medical condition(s) that may put the patient at risk or influence study results in the investigator's opinion, or that the investigator deems unsuitable for the study. |
Country | Name | City | State |
---|---|---|---|
United States | University of Maryland Medical Center | Baltimore | Maryland |
Lead Sponsor | Collaborator |
---|---|
CoapTech | University of Maryland Medical Center, University of Maryland, Baltimore |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Procedural Success | Rate of procedural success in completing jejunostomy tube placement using the PUMA-J System | Procedure timeframe | |
Secondary | Procedural Aborts | Description of occurrences of procedure abort | Procedure timeframe | |
Secondary | Device Related Serious Adverse Events | Rate of Device Related Adverse Events following Jejunostomy procedure | 48 hours of procedure performance | |
Secondary | Adverse Events | Rate of all Adverse Events following Jejunostomy procedure | 48 hours of procedure performance | |
Secondary | Rate of inadvertent puncture of vital organs | Description of occurrences of inadvertent puncture of vital organs during performance of procedure | Procedure timeframe | |
Secondary | Requirement for salvage surgery due to complication of the procedure | Description of occurrences of salvage surgery performed due to complication of procedure | 48 hours of procedure performance |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04485481 -
Single and Multiple Ascending Dose Study of ADX-914 in Healthy Adult Volunteers
|
Phase 1 | |
Completed |
NCT03473236 -
Phase 1A Safety Trial of Inhaled PK10571 (GB002)
|
Phase 1 | |
Not yet recruiting |
NCT03683953 -
The Treatment of Bronchopulmonary Dysplasia by Intratracheal Instillation of Mesenchymal Stem Cells
|
Phase 1 | |
Recruiting |
NCT05546567 -
NOPARK Open Label Extension Study
|
N/A | |
Recruiting |
NCT05413226 -
Effect of Different Ingestion Doses of Celastrol on Human Sperm Motility
|
N/A | |
Recruiting |
NCT05112159 -
Study of IPG1094 in Healthy Participants
|
Phase 1 | |
Completed |
NCT04689035 -
A Phase 1 Study in Healthy Volunteers to Evaluate the Safety, Tolerability and Pharmacokinetics of AVLX-144
|
Phase 1 | |
Completed |
NCT04335045 -
Phase I Study of PH100 (Ecklonia Cava Phlorotannins)
|
Phase 1 | |
Completed |
NCT05037227 -
Safety Profile Following Inactivated COVID-19 Vaccine in Healthy Adults Aged >18 Years in Indonesia
|
||
Recruiting |
NCT05517291 -
DCB Versus Primary Selective Stenting in TASC C/D Femoropopliteal Artery Disease
|
N/A | |
Enrolling by invitation |
NCT06446778 -
Haemodynamic Mechanisms and Multicentre Prospective Cohort Study of the Pipeline Flow-diverting Device for the Treatment of Intracranial Aneurysms. Evaluation of the Safety and Efficacy of the Pipeline Flow-diverting Device for the Treatment of Intracranial Aneurysms
|
||
Recruiting |
NCT04573049 -
The Effectiveness and Safety of Levosimendan in Patients With Severe Aortic Stenosis and Heart Failure Undergoing Transcatheter Aortic Valve Replacement
|
Phase 4 | |
Completed |
NCT05585463 -
Safety of Acupuncture and Intracutaneous Needles in Pediatric Cancer Patients: a Retrospective Study (ACUSAFE2021)
|
||
Completed |
NCT04188821 -
Reduction of Seroma and Improvement of QoL in Breast Reconstruction With Tissue Expander
|
N/A | |
Completed |
NCT03667430 -
Safety Evaluation of Porous Silica in Men
|
N/A | |
Completed |
NCT04499482 -
Safety and Tolerability of Soy Fiber
|
N/A | |
Completed |
NCT03141905 -
Sick-Day Protocol to Improve Outcomes in Chronic Kidney Disease
|
N/A | |
Completed |
NCT05244161 -
A Quasi-experimental Evaluation of the Malezi Program in Tanzania
|
N/A | |
Recruiting |
NCT03791372 -
Clinical Effect and Safety of Autologous Umbilical Cord Blood Transfusion in the Treatment of Cerebral Palsy
|
Phase 1 | |
Withdrawn |
NCT04759066 -
The HEALiX™ Intubated Patient (IP) Pilot Study
|
N/A |